NCT04270175 2026-02-27
Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab
Weill Medical College of Cornell University
Phase 2 Active not recruiting
Weill Medical College of Cornell University
Ohio State University Comprehensive Cancer Center
Samus Therapeutics, Inc.
Icahn School of Medicine at Mount Sinai
Ramsay Générale de Santé
Boston Medical Center
Prothena Biosciences Ltd.